Venture Funding Deals: Cell Medica Raises $73.2m, Tango Dances In With $55m

16 May 2017

• By Deanna Kamienski, Beth Allan, and Maureen Riordan

Novel approaches to infectious diseases and cancer garnered significant VC cash in recent months, including monoclonal antibodies to treat and prevent S. aureus, Cell Medica's next-generation T cell therapies and Tango's platform focused on genetic drivers of cancer.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in March and April 2017.

Arsanis Inc. raised $45.5m in its Series D financing led by the Bill & Melinda Gates Foundation, which was joined by other first-time backers GV and Alexandria Venture Investments, and returning shareholders OrbiMed, Polaris Venture Partners, SV Health Investors, NeoMed, EMBL Ventures and the Anna Maria and Stephen Kellen Foundation. (Also see "Finance Watch: OncoMed Cuts Costs To Conserve Capital While Public, Private Peers Raise Cash" - Scrip, 1 May, 2017

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

06 May 2025

• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.

Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives

05 May 2025

• By Mandy Jackson

Restructuring Edition: Unity unveiled more Phase IIb data for lead asset UBX1325 along with plans to shed its workforce while seeking a partner for it and other drugs. Also, Ono is consolidating US employees at one site, Entrada is cutting its workforce by 20% and other recent strategic shifts.

Finance Watch: Biohaven Gains Up To $600m In Fresh Capital

02 May 2025

• By Mandy Jackson

Public Company Edition: Biohaven secured $250m up front from Oberland Capital to support its future US troriluzole launch after pulling its EU filing. Also, Procaps arranged $130m in private equity and Rezolute grossed $96.9m in a rare follow-on offering, among other financings.

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

01 May 2025

• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.